ZENTALIS PHARMACEUTICALS INC. - COMMON STOCK

Zentalis Pharmaceuticals to Participate in Two Upcoming Investor Conferences

31 8 2022 07:00:00 提供 Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Reports Second Quarter 2022 Financial Results and Operational Update

09 8 2022 16:01:00 提供 Nasdaq GlobeNewswire

Zentalis Pharmaceuticals to Participate in the Wedbush PacGrow Healthcare Conference

03 8 2022 07:00:01 提供 Nasdaq GlobeNewswire

Zentalis Pharmaceuticals, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

01 8 2022 17:10:35 提供 Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Appoints Andrea Paul as General Counsel and Corporate Secretary

27 6 2022 07:00:00 提供 Nasdaq GlobeNewswire

Zentalis Pharmaceuticals to Participate in the Jefferies Healthcare Conference

01 6 2022 07:00:01 提供 Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Promotes Cofounder Cam Gallagher to President

31 5 2022 07:00:00 提供 Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Announces Closing of Underwritten Offering of Common Stock

18 5 2022 16:01:00 提供 Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Announces Pricing of Underwritten Offering of Common Stock

16 5 2022 07:28:36 提供 Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Appoints Oncology Clinical Development Veteran Dr. Kimberly Blackwell as Chief Executive Officer

16 5 2022 07:00:01 提供 Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Reports First Quarter 2022 Financial Results and Operational Update

05 5 2022 07:00:03 提供 Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Announces $25 Million Equity Investment from Pfizer

27 4 2022 07:00:01 提供 Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Announces Overview of Clinical and Preclinical Data Presented at AACR

11 4 2022 16:01:00 提供 Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Announces Positive Initial Clinical Data on ZN-c3, its Wee1 Inhibitor, in Patients with Advanced Ovarian Cancer at AACR

08 4 2022 13:00:00 提供 Nasdaq GlobeNewswire

Zentalis Pharmaceuticals and Caris Life Sciences Announce Strategic Collaboration to Support Clinical Studies, Initially Focused on the Wee1 Inhibitor ZN-c3

29 3 2022 07:00:00 提供 Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Announces First Patient Dosed in the Potentially Registrational Phase 1/2 Study of BCL-2 inhibitor ZN-d5 in Patients with Relapsed or Refractory Light Chain (AL) Amyloidosis

22 3 2022 07:00:01 提供 Nasdaq GlobeNewswire

Zentalis Pharmaceuticals to Present at the Oppenheimer Annual Healthcare Conference

09 3 2022 16:01:00 提供 Nasdaq GlobeNewswire

Zentalis Pharmaceuticals to Present New Clinical and Preclinical Data at the AACR Annual Meeting 2022

08 3 2022 16:30:00 提供 Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Update

24 2 2022 07:00:01 提供 Nasdaq GlobeNewswire

Zentalis Pharmaceuticals to Participate in Two Upcoming Investor Conferences

03 2 2022 07:00:01 提供 Nasdaq GlobeNewswire